News & Reports

Have some news you want to share with the Oregon Bio community?  Fill out our submission form.

Gilead Sciences statement on New England Journal of Medicine’s publication of Remdesivir data from NIAID study

Foster City, Calif., May 22, 2020 – Gilead Sciences today issued the following statement from Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences, on data from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of our investigational antiviral drug remdesivir, published in The New England Journal of Medicine (NEJM):

“We are pleased that the findings from the NIAID trial of remdesivir in hospitalized patients with advanced COVID-19 have been published in a peer-reviewed medical journal. These findings support […]

May 26, 2020 |

BIO Appoints a physician-scientist as new president and CEO

Immunologist Michelle McMurry-Heath is Selected for Her Global Leadership and Commitment to Innovation and Patients

Former FDA Official Will Succeed Industry Leader Jim Greenwood on June 1 as Leader of World’s Largest Biotechnology Advocacy Association

May 14, 2020 

WASHINGTON–(BUSINESS WIRE)–The Biotechnology Innovation Organization (BIO) – the world’s largest science and public advocacy organization, representing 1,000 members — announced today that Michelle McMurry-Heath, MD, PhD, will become the organization’s next President and CEO on June 1, succeeding former Rep. Jim […]

May 19, 2020 |

Bio forward: In the post COVID-19 world, local bioscience is solving and serving innovation

As we emerge from the pandemic, our Oregon and southwest Washington sectors of biotech, medical device, diagnostics and health IT are at the forefront of providing lifesaving and health-improving solutions like never before in history – from therapeutics to vaccines to testing to clinical trials to sterilization to PPE manufacturing to telehealth to tracing and tracking.  A growth industry with high paying jobs, our bioscience industry answered the call and will continue to play a pivotal role in our region’s […]

May 12, 2020 |

Oregon General Guidance for Employers on COVID-19

Oregon Health Authority issued general guidance for employers that applies statewide starting May 15. The document includes a link to Oregon’s specific guidelines for sectors including healthcare and personal services. Click the thumbnail to view the guidance.

Madorra featured in O Magazine’s May issue spotlighting rising femtech businesses

FemTech innovator Madorra Medical is empowering women to live fuller, healthier lives. The Oprah Magazine featured the Oregon based company that is working towards changing the paradigm for treating vaginal dryness. Madorra provides a medical device solution to a problem that has previously only been served by pharmaceuticals. They are focused on giving post-menopausal women and breast cancer survivors the power to choose a non-hormonal treatment option. Learn more Here

New Grant Funding Launched to Develop Technologies Related to Combating COVID-19

This week, Business Oregon and the Oregon Innovation Council (Oregon InC) announced the Enhanced Innovation Grant Program that will fund up to five proposals from innovation-based companies that either show an ability to commercialize a technology that will help address the COVID-19 crisis and move to economic recovery or Oregon InC portfolio companies that are poised to commercialize their product.

Oregon InC supports companies with high-growth potential emerging from science and research. In 2018-2019, Oregon InC invested a total of $2,510,251 […]

New SEC rules will help small biotechs deliver the medicines we need

Good Day Bio, April 28, 2020 – https://go.bio.org/index.php/email/emailWebview

Amidst the countless coronavirus headlines, you might have missed this news: changes to SEC rules just went into effect that will offer welcome relief for small biotech companies and help them deliver the new medicines we need. Here’s the scoop.

Catch me up! The Securities and Exchange Commission (SEC) adopted regulatory changes providing small public companies with a temporary exemption from compliance with Sarbanes-Oxley Act of 2002 Section 404(b), which requires public companies to […]

April 28, 2020 |

New member HealthSaas engineers AI and rolls out COVID-19 AI check-up tool

Oregon Bio welcomes new member HealthSaaS, the local powerhouse steering cognitive population health management through an ‘Internet of Things’ approach. And, it’s empowering a new standard of interactive and predictive healthcare through a new offering called CarePath AI.

And now, HealthSaas has teamed up with AkēLex and Hewlett Packard to employ those same tools to safely detect and track infectious conditions such as COVID-19. As a public service, HealthSaaS has developed a free, AI-powered screening tool, “COVID-19 Checkup” which […]

AdvaMed and Portland-metro based Acumed welcome administration’s announcement on elective surgeries

On April 16, federal administrators gave the green light to resume elective surgeries during their coronavirus briefing. The decision is part of the larger plan to gradually reopen the country as the coronavirus pandemic plays out.

AdvaMed President and CEO Scott Whitaker released the following statement, “We appreciate the President’s announcement tonight of a plan that would safely allow elective surgeries to resume. The term ‘elective surgeries’ implies they’re procedures patients choose to have, but in reality means surgeries or procedures that […]

April 21, 2020 |

Virtual Venture Day with Taiho Ventures – Apply by April 23rd 

Oregon Bio is pleased to provide members with the opportunity to apply to meet with Taiho Ventures, where select members looking to raise capital will join us for a series of one-on-one meetings, scheduled to take place virtually on Thursday, May 7th.

Taiho Ventures, LLC is the strategic corporate venture capital arm of Taiho Pharmaceutical Co., Ltd., a Japanese specialty pharma focusing on oncology, allergy and immunology, and urology. Taiho Ventures is looking at early-stage preclinical therapeutics companies as well as platform […]

Melinta wins bidding war to land deal to acquire Tetraphase ntaylor Fri, 06/05/2020 - 07:50

After Kaletra setback, AbbVie joins forces with biotech, academia for experimental COVID-19 hopeful badams Fri, 06/05/2020 - 07:06

Another venture capital firm that backs biotechs has raised a multimillion-dollar fund—money the firm, Cambridge, MA-based Atlas Venture, says it will use to continue creating and funding companies th

Bristol's Celgene merger sees it bounce Jounce drug pact badams Fri, 06/05/2020 - 05:32

Atlas banks $400M in its latest 'breakthrough biotech' fund aalidrus Thu, 06/04/2020 - 21:33

Chutes & Ladders--WuXi adds Celgene vet Chang to head CAR-T offerings kblankenship Thu, 06/04/2020 - 18:30

AstraZeneca is looking to bolster its cancer R&D portfolio with therapies that target RNA-modifying enzymes and other proteins involved in cancer. On Thursday the Cambridge, UK-based pharma giant

What does it mean to #BeFierce? Our new look tells the story rwillumson Thu, 06/04/2020 - 15:38